^
Association details:
Biomarker:RUNX1-RUNX1T1 fusion
Cancer:Acute Myelogenous Leukemia
Regimen:DAV
Direction:Sensitive
Evidence:
Evidence Level:
Sensitive: C3 – Early Trials
New
Source:
Title:

Outcomes of different therapies in acute myeloid leukemia patients with core-binding factor.

Published date:
05/25/2023
Excerpt:
In the RUNX1:RUNXT1 fusion subgroup, DAV group showed significantly improved OS and event-free survival (EFS) than other groups, while VA groups was the worst….Our study demonstrated a promising therapeutic results of DAV regimen, and an unsatisfactory therapeutic results of VA regimen in CBF-AML. CBF-AML patients showed significantly improved CR rate, elimination of fusion genes, OS, and EFS when received intense chemotherapy, especially DAV and HAA regimen, than VA regimen.
DOI:
10.1200/JCO.2023.41.16_suppl.e19036